Navenibart - Astria Therapeutics
Alternative Names: QLS-215; STAR-0215Latest Information Update: 22 Apr 2024
At a glance
- Originator Quellis Biosciences
- Developer Astria Therapeutics
- Class Monoclonal antibodies; Plasma expanders; Skin disorder therapies; Vascular disorder therapies
- Mechanism of Action Plasma kallikrein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hereditary angioedema
Most Recent Events
- 25 Mar 2024 Astria Therapeutics completes enrolment in its phase I/II trial for Hereditary angioedema in the US, Bulgaria, Canada, Germany and UK (NCT05695248) (EudraCT-2022-502953-32)
- 25 Mar 2024 Astria Therapeutics plans to initiate a pivotal Q3M phase III trial in Q1 2025 (Parenteral)
- 25 Mar 2024 Initial efficacy and adverse event data from the phase Ib/II ALPHA-STAR trial in Hereditary angioedema released by Astria Therapeutics